NASDAQ:SGP

Spyglass Pharma (SGP) Stock Price, News & Analysis

Spyglass Pharma logo
$30.78 +1.10 (+3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$30.72 -0.07 (-0.21%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Spyglass Pharma Stock (NASDAQ:SGP)

Advanced

Key Stats

Today's Range
$27.94
▼
$31.21
50-Day Range
$23.69
▼
$38.37
52-Week Range
$17.06
▼
$39.92
Volume
86,423 shs
Average Volume
123,133 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.83
Consensus Rating
Moderate Buy

Company Overview

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops.

The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period.

SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development. The company has not established a broad commercial product portfolio.

AI Generated. May Contain Errors.

Spyglass Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

SGP MarketRank™: 
3.50957592339 of 5 stars

Spyglass Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 201st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spyglass Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Spyglass Pharma has a consensus price target of $45.83, representing about 48.9% upside from its current price of $30.78.

  • Amount of Analyst Coverage

    Spyglass Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Spyglass Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Spyglass Pharma are expected to decrease in the coming year, from ($2.77) to ($2.93) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spyglass Pharma is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spyglass Pharma is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spyglass Pharma has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.47% of the float of Spyglass Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Spyglass Pharma has a short interest ratio ("days to cover") of 12.05, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Spyglass Pharma has recently decreased by 5.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Spyglass Pharma does not currently pay a dividend.

  • Dividend Growth

    Spyglass Pharma does not have a long track record of dividend growth.

  • News Sentiment

    Spyglass Pharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Spyglass Pharma this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for SGP on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Spyglass Pharma to their MarketBeat watchlist in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $32,430.00 in company stock, which represents 0.0031% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Spyglass Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,430.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Institutions

    Spyglass Pharma has minimal institutional ownership at this time.

  • Read more about Spyglass Pharma's insider trading history.
Receive SGP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spyglass Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGP Stock News Headlines

Spyglass Pharma (NASDAQ:SGP) Price Target Raised to $44.00
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
SpyGlass Pharma (SGP) Ratios
See More Headlines

SGP Stock Analysis - Frequently Asked Questions

Spyglass Pharma's stock was trading at $27.69 on February 17, 2026. Since then, SGP stock has increased by 11.2% and is now trading at $30.78.

Spyglass Pharma, Inc. (NASDAQ:SGP) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.07.

Spyglass Pharma (SGP) raised $150 million in an initial public offering (IPO) on Friday, February 6th 2026. The company issued 9,375,000 shares at $15.00-$17.00 per share.

Shares of SGP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/19/2026
Citi Annual Global Healthcare Conference 2026
12/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SGP
CIK
1778922
Fax
N/A
Employees
65
Year Founded
2019

Price Target and Rating

High Price Target
$62.00
Low Price Target
$39.00
Potential Upside/Downside
+48.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($7.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.87 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-47.46%
Return on Assets
-33.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.24
Quick Ratio
15.24

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.29 per share
Price / Book
4.89

Miscellaneous

Outstanding Shares
33,460,000
Free Float
N/A
Market Cap
$1.03 billion
Optionable
N/A
Beta
N/A

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:SGP) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners